TY - JOUR AU - Dong, Liang AU - Xia, Jingwen AU - Zhang, Jing AU - Zhang, Yuanyuan AU - Zhu, Ning AU - Zhang, Peng AU - Zhang, Youzhi AU - Zhang, Xiujuan AU - Li, Shengqing PY - 2018 DA - 2018/01/23 TI - Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report JO - BMC Pulmonary Medicine SP - 13 VL - 18 IS - 1 AB - Crizotinib is recommended as first-line therapy in ROS1-driven lung adenocarcinoma. However, the optimal first-line therapy for this subgroup of lung cancer is controversial according to the available clinical data. SN - 1471-2466 UR - https://doi.org/10.1186/s12890-018-0585-9 DO - 10.1186/s12890-018-0585-9 ID - Dong2018 ER -